BRPI0417241A - agente e processo para a prevenção e/ou para o tratamento de disfunção do cérebro superior, e, uso de um derivado de xantina, ou um sal farmaceuticamente aceitável do mesmo - Google Patents

agente e processo para a prevenção e/ou para o tratamento de disfunção do cérebro superior, e, uso de um derivado de xantina, ou um sal farmaceuticamente aceitável do mesmo

Info

Publication number
BRPI0417241A
BRPI0417241A BRPI0417241-8A BRPI0417241A BRPI0417241A BR PI0417241 A BRPI0417241 A BR PI0417241A BR PI0417241 A BRPI0417241 A BR PI0417241A BR PI0417241 A BRPI0417241 A BR PI0417241A
Authority
BR
Brazil
Prior art keywords
acceptable salt
agent
xanthine derivative
prevention
brain dysfunction
Prior art date
Application number
BRPI0417241-8A
Other languages
English (en)
Inventor
Hiroshi Kase
Yutaka Nakagawa
Shizuo Shiozaki
Minoru Kobayashi
Shinichiro Toki
Naoki Seno
Ken Ikeda
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Publication of BRPI0417241A publication Critical patent/BRPI0417241A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/12—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1, 3, and 7, e.g. caffeine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"AGENTE E PROCESSO PARA A PREVENçãO E/OU PARA O TRATAMENTO DE DISFUNçãO DO CéREBRO SUPERIOR, E, USO DE UM DERIVADO DE XANTINA, OU UM SAL FARMACEUTICAMENTE ACEITáVEL DO MESMO". Um agente preventivo e/ou terapêutico para disfunções do cérebro superior que contém, como um ingrediente ativo, um derivado de xantina representado, por exemplo, pela fórmula (I) a seguir ou por um sal farmacologicamente aceitável da mesma: (I) (II) em que R¬ 1¬, R¬ 2¬ e R¬ 3¬ são os mesmos ou diferentes e cada um representa hidrogênio, alquila inferior, alquenila inferior ou alquinila inferior; R¬ 4¬ representa cicloalquila, -(CH~ 2~)~ n~-R¬ 5¬ ou a fórmula (II) fornecida a seguir e X¬ 1¬ e X¬ 2¬ são os mesmos ou diferentes e cada um representa oxigênio ou enxofre.
BRPI0417241-8A 2003-12-09 2004-12-09 agente e processo para a prevenção e/ou para o tratamento de disfunção do cérebro superior, e, uso de um derivado de xantina, ou um sal farmaceuticamente aceitável do mesmo BRPI0417241A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003410432 2003-12-09
PCT/JP2004/018765 WO2005056016A1 (ja) 2003-12-09 2004-12-09 高次脳機能障害の予防および／または治療剤

Publications (1)

Publication Number Publication Date
BRPI0417241A true BRPI0417241A (pt) 2007-03-06

Family

ID=34674933

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417241-8A BRPI0417241A (pt) 2003-12-09 2004-12-09 agente e processo para a prevenção e/ou para o tratamento de disfunção do cérebro superior, e, uso de um derivado de xantina, ou um sal farmaceuticamente aceitável do mesmo

Country Status (10)

Country Link
US (1) US20070078148A1 (pt)
EP (1) EP1709966A4 (pt)
JP (1) JPWO2005056016A1 (pt)
KR (1) KR20060124615A (pt)
CN (1) CN1889959A (pt)
AU (1) AU2004296137A1 (pt)
BR (1) BRPI0417241A (pt)
CA (1) CA2550130A1 (pt)
WO (1) WO2005056016A1 (pt)
ZA (1) ZA200604723B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9101580B2 (en) 2012-12-18 2015-08-11 Matthew Bennett Compositions and methods for treating traumatic brain injury

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4755517A (en) * 1986-07-31 1988-07-05 Warner-Lambert Company Derivatives of xanthine, pharmaceutical compositions and methods of use therefor
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
FR2665636B1 (fr) * 1990-08-10 1994-10-07 Adir Utilisation d'un derive de la trimethyl-1,3,7 xanthine pour le traitement des troubles de la memoire, des troubles intellectuels de la senescence et de la maladie d'alzheimer.
AU680241B2 (en) * 1993-02-26 1997-07-24 Merrell Pharmaceuticals Inc. Xanthine derivatives as adenosine A1 receptor antagonists
US5703085A (en) * 1994-02-23 1997-12-30 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
ATE325610T1 (de) * 1997-09-05 2006-06-15 Kyowa Hakko Kogyo Kk Xanthinderivative zur behandlung von hirnischämie
DE60228073D1 (de) * 2001-05-08 2008-09-18 Brni Neurosciences Inst Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen
AR056615A1 (es) * 2002-12-27 2007-10-17 Kyowa Hakko Kogyo Kk Un metodo de tratamiento de trastornos de la conducta

Also Published As

Publication number Publication date
CN1889959A (zh) 2007-01-03
US20070078148A1 (en) 2007-04-05
WO2005056016A1 (ja) 2005-06-23
EP1709966A4 (en) 2009-04-29
ZA200604723B (en) 2009-11-25
EP1709966A1 (en) 2006-10-11
JPWO2005056016A1 (ja) 2007-07-05
KR20060124615A (ko) 2006-12-05
CA2550130A1 (en) 2005-06-23
AU2004296137A1 (en) 2005-06-23

Similar Documents

Publication Publication Date Title
BRPI0418082A (pt) antagonista de receptor de adenosina a2a, agente para tratar e/ou prevenir doenças, composto, composição farmacêutica, e, método para tratar e/ou prevenir doenças associadas com receptor de adenosina a2a
BR0015624A (pt) Uso de um composto, composto, composição farmacêutica, e, método de tratamento ou profilaxia de doenças ou condições humanas
AU2003301020A8 (en) Isoquinolinone derivatives and their use as therapeutic agents
RS74904A (en) Substituted pyridinones as modulators of p38 map kinase
BRPI0314308B8 (pt) antagonistas de opióide, seus usos, e composição farmacêutica
NO20050217L (no) Nye quinuklidin-karbamat-derivater samt medisinske sammensetninger inneholdende slike
BRPI0708038B8 (pt) derivado de cumarina, composição farmacêutica e agente terapêutico para um distúrbio proliferativo celular
BRPI0407283A (pt) Composto, composição farmacêutica, e, agente ativador de glucoquinase, agentes terapêuticos e/ou agentes preventivos para diabetes melito e obesidade
TW200517109A (en) Substituted pyridinones
ECSP045139A (es) DERIVADOS DE ACETILENO QUE TIENEN ACTIVIDAD ANTAGONISTICA DE MGluR5
NO20021328L (no) Pyrazolopyrimidier som terapeutiske midler
BRPI0517423A (pt) composto, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com disfunção do glutamato em um animal, e, uso em um composto
BR0311806A (pt) Derivados heteroaril benzocondensado-amida de tienopiridinas úteis como agentes terapêuticos, composições farmacêuticas que os incluem e métodos para o seu uso
EP1201239A4 (en) CYCLIC AMINES AS CCR3 ANTAGONISTS
UA85708C2 (ru) Лекарственные комбинации, содержащие бензоксазины, для лечения заболеваний дыхательных путей
BR0213464A (pt) Derivados de 3-azabiciclo[3.1.0]hexano como antagonistas receptores de opióide
NO990433L (no) Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet
EA200400466A1 (ru) Производные пиперазина с антагонистической активностью к рецептору ccr1
MXPA04005209A (es) Antagonistas del receptor de adenosina a2a.
DE60100994D1 (de) Transdermales therapeutisches System für die Erzielung hoher Plasmaspiegel von Rotigotin in der Therapie von Morbus Parkinson
BR0315777A (pt) Uso de derivados de piperazina como antagonistas ccr1
BRPI0414011A (pt) naftalencarboxamidas e seus derivados úteis como novos agentes antiangiogênicos
YU75603A (sh) Dihidropirimidinska jedinjenja koja su supstituisana na cijano grupi i njihova upotreba u lečenju oboljenja
BR0210238A (pt) Novos análogos de aril-amino-propano e seu uso para o tratamento de glaucoma
DE69834500D1 (de) Xanthinderivative zur behandlung von hirnischämie

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.